2
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
19
Neoplasms
11
Polycystic Ovary Syndrome
9
Neoplasm Metastasis
4
Multiple Myeloma
4
Melanoma
4
Vomiting
3
Prostatic Neoplasms
3
Leukemia, Myeloid, Acute
3
Leiomyoma
3
Head and Neck Neoplasms
3
Endometrial Neoplasms
3
Triple Negative Breast Neoplasms
2
Solid Tumors
2
Skin Neoplasms
2
Sarcoma
2
Recurrence
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Peripheral Nervous System Diseases
2
Ovarian Neoplasms
2
Obesity
2
Nausea
2
Myofibroma
2
Lung Neoplasms
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia, B-Cell
2
Leukemia
2
Insulin Resistance
2
Inflammation
2
Infertility, Female
2
Interventions
rozanolixizumab
11
efgartigimod alfa
10
zilucoplan
8
Prednisone
8
Cyclophosphamide
8
ravulizumab
7
Rituximab
7
Pyridostigmine Bromide
7
telitacicept
6
fludarabine
6
Tacrolimus
6
Mycophenolic Acid
6
eculizumab
5
Immunoglobulins, Intravenous
5
Hizentra
4
Azathioprine
4
Steroids
3
HBM9161
3
Data Collection
3
Amifampridine
3
thymoglobulin
2
inebilizumab
2
Thymectomy
2
Prednisolone
2
Methylprednisolone
2
Methotrexate
2
Exercise
2
Diagnostic Self Evaluation
2
Blood Specimen Collection
2
tofacitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myasthenia Gravis
×
Tablets
×
Clear all
NCT03914638
2020-04-06
BETA-MG
University of Aarhus
Phase 2/3
Unknown
30 enrolled